Introduction
============

Physical and mental threat can induce fear responses, and fear can be associated with objects and places through a process of Pavlovian fear conditioning (Ledoux, [@B21]). The process of fear learning and, importantly, its "overriding" or fear extinction is dependent on the amygdala and the prefrontal cortex (PFC). Stress is a multi-dimensional challenge to physical and mental homeostasis that can be triggered by fear (Kim and Diamond, [@B19]; McEwen, [@B26]), and both acute and chronic stress can alter the properties of fear (Conrad et al., [@B8]; Rodrigues et al., [@B33]). A growing body of evidence suggests that fear and traumatic stress may contribute to the pathophysiology of suicide. For instance, suicidal ideation was significantly associated with traumatic life events and the effects of traumatic stress on suicidal behavior may be mediated by feelings of hopelessness (Tarrier and Picken, [@B38]; Guerra and Calhoun, [@B13]). A study using a large scale of civilian population (*N* = 34,653) found that over 70% of the individuals who reported a lifetime history of a suicide attempt had anxiety disorders (Nepon et al., [@B27]). Interestingly, individuals with comorbidity of personality disorders such as neuroticism and posttraumatic stress disorder (PTSD) showed a much stronger association with suicide attempts than those who had PTSD alone. In a military population, more U.S. service members have been deployed since September 2001 than in the previous 40 years. A greater number of these deployed service members are surviving, which has increased the incidence of combat-related PTSD among those veterans (Callahan, [@B3]). For example, Iraq and Afghanistan War veterans who showed PTSD symptoms were four times more likely to endorse suicidal ideation than their non-PTSD counterparts (Jakupcak et al., [@B18]). These evidences suggest that fearful memories and PTSD symptoms may contribute to suicidal ideation and attempts, and individual vulnerability to traumatic events is one of the risk factors for suicide (Ursano et al., [@B42]). However, precise molecular mechanisms underlying how fear and stress trigger suicidal behavior in humans are not clearly understood.

Multiple brain regions have been implicated in emotional learning and memory. Among those, the PFC is one of the key brain regions that integrates stress signals and subsequent decision-making process in humans. Protein phosphorylation in the brain plays a critical role in triggering synaptic changes that are associated with emotional learning and memory (Fischer et al., [@B10]). Intracellular phosphorylation is orchestrated by a complex network of many different kinases including protein kinase C (*PKC*), calcium/calmodulin-dependent protein kinase (*CAMK*), mitogen-activated protein kinase (*MAPK*), and cyclin-dependent kinase (*CDK*). *PKC* is a critical phosphorylating enzyme in the phosphoinositide signaling pathway. Previous studies have suggested that these kinases such as *PKC, CAMK, MAPK*, and *CDK* also regulate fear conditioning and extinction in animals (Schafe et al., [@B35]; Li et al., [@B23]; Frankland et al., [@B11]; Lepicard et al., [@B22]; Sananbenesi et al., [@B34]; Bergstrom et al., [@B1]). For example, chronic administration of a *PKC* inhibitor reduced the acquisition of conditioned fear memory suggesting the involvement of *PKC* in the synaptic plasticity and memory (Li et al., [@B23]). On the contrary, another study reported that inhibition of *PKC* signaling protected dendritic spines in the PFC and rescued working memory impairment caused by chronic stress (Hains et al., [@B14]). The authors suggested that *PKC* inhibitors may act as neuroprotective agents in fear and stress-related disorders. *CAMK* is also involved in hippocampal-dependent contextual learning in rodents (Kouzu et al., [@B20]). Among the individuals with psychiatric disorders, the expression levels of *CaMKII* beta (*CAMK2B*) were increased in the PFC of individuals with schizophrenia (27%) and individuals with depression (36%) as compared to the unaffected controls (Novak et al., [@B28]). Because *CAMK2B* regulates important functions in the brain such as neurotransmitter signaling, neural outgrowth, and pruning, its increased expression in the PFC of the individuals with psychiatric disorders may have important implications. Moreover, inhibition of the *MAPK* pathway in the hippocampus abolished the increased contextual fear conditioning induced by glucocorticoids in mice (Revest et al., [@B32]). This suggests that the *MAPK* pathway interacts with the glucocorticoid system in fear learning and memory. Another kinase, cyclin-dependent kinase 5 (CDK5), has been implicated in learning and memory (Fischer et al., [@B10]). *CDK5* plays a role during neurodevelopmental processes, such as interactions with distinct cytoplasmic and synaptic target molecules, and synaptic plasticity underlying memory consolidation in the adult brain. It has been shown that extinction of fear memory requires down-regulation of *CDK5* activity in the mouse hippocampus (Sananbenesi et al., [@B34]). Taken together, these studies indicate that multiple kinase systems contribute to regulation of emotional learning and memory, and subsequent behavioral responses in animals and in humans.

Recent advances in genomic technologies utilizing postmortem brain tissue have made significant progress toward more analytical and informative research in psychiatry (Harrison, [@B15]; Mccullumsmith and Meador-Woodruff, [@B25]). However, identifying potential susceptibility genes associated with suicide has been challenging (Mann et al., [@B24]; Tsai et al., [@B41]). We have shown that gene expression changes in postmortem brain tissue are subtle possibly due to a relatively small sample size, known and unknown confounding factors, and diagnostic heterogeneity among psychiatric patients (Choi et al., [@B4]). Given that multiple kinase genes are implicated in the mechanisms of fear and stress, and fear and stress are the major risk factors for suicidal behavior, we hypothesized that the kinases genes may be involved in the pathophysiology of suicidal behavior. Thus, we investigated the expression profiles of four major kinase genes including protein kinase C (*PKC*), calcium/calmodulin-dependent protein kinase (*CAMK*), mitogen-activated protein kinase (*MAPK*), and *CDK* in the PFC of mood disorder patients died with and without suicide. In order to study the developmental expression pattern of the same genes, we measured mRNA levels in the PFC of normal individuals ranging in age from birth to 49 years. Using gene expression microarrays from the postmortem brain tissue, we aimed to identify potential kinase genes that are associated with both chronological age and suicide.

Materials and Methods
=====================

Postmortem brain tissue
-----------------------

Gene expression microarray datasets from the individuals with mood disorders with suicide (*N* = 45) and without suicide (*N* = 38) were obtained from the Stanley Online Genomics database (see text footnote 1). The details of the brain sample collection have been described previously (Torrey et al., [@B40]). Developmental brain tissue from the PFC of subjects (*N* = 46) ranging in age from 1 month to 49 years was obtained from the National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders (UMBB; NICHHD contract\# NO1-HD8-3283). The collection protocol was reviewed and approved by the Institutional Review Board of the University of Maryland, Baltimore. For the developmental brains, all subjects were free of neurological and psychiatric symptoms at the time of death as described previously (Choi et al., [@B5]). Developmental brain microarray raw data are available from the gene expression omnibus (GEO) with an Accession number GSE11512.

Microarray experiment
---------------------

Total RNA was extracted from gray matter of the PFC (BA 46) and using the Trizol method (Invitrogen, Carlsbad, CA, USA). Samples were included only if the RNA was of good quality (RNA integrity number, RIN \> 7) as determined by the Bioanalyzer 2100 electrophoresis system (Agilent Technologies, Foster City, CA, USA). Purified RNA was carried through the Affymetrix preparation protocol[^2^](#fn2){ref-type="fn"}, and each sample was hybridized to the different Affymetrix platform such as HGU95av2, HGU 133a, HGU 133b, or HGU133 plus 2.0 GeneChip to assess genome-wide expression profiles. RNA processing and microarray data generation was performed by the individual investigators at their own facilities as described previously (Choi et al., [@B4]).

Quality control of microarrays
------------------------------

Raw microarray data were processed and analyzed using the R statistical language[^3^](#fn3){ref-type="fn"} and the Bioconductor packages (Gentleman et al., [@B12]). A robust multi-array average (RMA) algorithm was used for normalization of expression values (log base 2) for each transcript (Irizarry et al., [@B17]). Microarray data quality was assessed using a pair-wise sample correlation coefficient with hierarchical clustering. Transcripts were filtered out if 20% or more of the subjects had expression values of less than a 1.1-fold change in either direction from the transcript\'s median value and if the percent of subjects with an absent gene call exceeded 33% using the Affymetrix calls.

Microarray analysis of the developmental brains
-----------------------------------------------

First, we analyzed individual demographic factors including brain pH, postmortem interval (PMI), RIN, race, and sex to identify potential confounds affecting the expression of a significant number of genes (*p* \< 0.001). Following the demographic variable analyses, gene expression across chronological age was analyzed in a series of multiple regression models, one model for each gene, including age (log base 2) and brain pH as independent variables and gene expression (log base 2) as a dependent variable (Choi et al., [@B5]). To correct for multiple testing of the genes, the calculated *p*-values corresponding to the age covariate for each gene were adjusted to give an overall false discovery rate (FDR) of 5% using the *q*-value (*q*v) package[^4^](#fn4){ref-type="fn"}. The criteria of significance were set at *q*v \< 0.05.

Microarray analysis of mood disorder with and without suicide
-------------------------------------------------------------

Mood disorder subjects were divided into two groups: those with suicide (*N* = 45) and those without suicide (*N* = 38). Each pre- and post-mortem variable was compared between the suicide and the non-suicide group. We identified the variables including age, mood disorder, and duration of illness that were different between the two groups (*p* \< 0.05). Thus, we adjusted for these variables in the following suicide analysis using multiple regression models. For an individual study analysis, we performed a linear regression analysis to calculate an adjusted fold change, SE, and *p*-value for each gene in each study. We then performed a cross-study comparison based on scaled representations of individual study-level analysis across nine microarray studies. Consensus fold change was calculated for each gene based on a weighted combination of the individual fold changes and the SEs for the microarray probe sets that map to each gene across the studies as described previously (Choi et al., [@B4]). Weights were determined in a probe set specific manner to account for the different levels of precision associated with each probe set that map to a given gene across the studies. The weights were equal to 1/SE*i*, where SE*i* is the SE of the *i*th probe set for the gene across all the studies. To adjust for multiple testing of the genes, the calculated *p*-values corresponding to the suicide group were adjusted to give an overall FDR of 5% using the *q*v package. The criteria of significance were set at *q*v \< 0.05 and fold change \>1.1.

Bioinformatics mappings
-----------------------

The NCBI\'s Database for Annotation, Visualization, and Integrated Discovery was used as the standard source for gene annotation information \[22\]. The primary fields extracted from the DAVID include: Entrez ID, gene symbol, gene name, and gene summary. For the microarrays, queries were based on the Affymetrix probe set ID (AFFYID).

Results
=======

A summary of the subject characteristics included in the microarray studies is shown in Table [1](#T1){ref-type="table"}. There were no significant differences in sex, race, brain pH, and PMI between the suicide and the non-suicide group; this is important since these pre- and post-mortem variables appear to influence gene expression in the postmortem brain tissue. The number of bipolar disorder subjects was slightly higher in the non-suicide group (66 vs. 51%) while the number of major depression subjects was higher in the suicide group (49 vs. 34%). Other variables such as age (47.2 vs. 41.7) and duration of illness (19.4 vs. 15) were different between the suicide and the non-suicide group (*p* \< 0.05). Thus, we adjusted for age, mood disorder (bipolar disorder and major depression) and duration of illness in the following suicide analysis using a multiple regression model. Among the 45 suicide cases, a majority of the subjects died of drug overdose (36%), hanging (29%), jumped (11%), and gun shot wound (9%).

###### 

**A summary of subject characteristics included in suicide microarray analysis**.

                            Non-suicide    Suicide
  ------------------------- -------------- -------------
  Number of subjects        38             45
  Age                       47.2 (1.6)     41.7 (1.6)
  Sex (male)                55.3%          55.6%
  Race (caucasian)          94.7%          95.6%
  Bipolar disorder          65.8%          51.1%
  Major depression          34.2%          48.9%
  PMI                       32.9 (2.5)     33.0 (2.3)
  Brain pH                  6.4 (0.05)     6.5 (0.04)
  Duration of illness       19.4 (1.7)     15.0 (1.4)
  Lifetime antipsychotics   11287 (4021)   4981 (1707)

*For each variable, mean* ± *SE or percentage value is reported. PMI, postmortem interval*.

Figure [1](#F1){ref-type="fig"} shows the expression profiles of *CAMK2B* in the PFC of normal individuals ranging in age from birth to 49 years (A) and suicide victims as compared to the non-suicide subjects (B). The expression levels of *CAMK2B* in the PFC were gradually decreased during the postnatal development (*r*^2^ = 0.69, *q*v = 1.1E-11). Each subject was color-coded based on the arbitrary age group such as neonate (red), infant (green), toddler (blue), school age (magenta), teenage (pink), young adult (yellow), and adult (gray). A combined analysis of the microarray studies shows that *CAMK2B* expression levels are significantly increased in the PFC of suicide victims as compared to the non-suicide subjects (FC: 1.13, *q*v = 0.009). There are multiple microarray probes (*N* = 2--5) for *CAMK2B* in each study and those probes show consistent changes in expression levels. Although most of the individual studies did not show significant changes, the combined analysis (shown on the bottom) showed consensus increases in expression in the suicide group as compared to the non-suicide group.

![**The expression profiles of ***CAMK2B*** in the PFC of normal developing individuals and suicide victims**. **(A)** The scatter plot with a locally weighted scatter plot smoothing (LOWESS) line demonstrates gradual decreases in expression levels of *CAMK2B* in the PFC of normal humans ranging in age from birth to 49 years. Points are colored by the predefined age groups: red = neonate, green = infant, blue = toddler, light blue = school age, pink = teenage, yellow = young adult, gray: adult. **(B)** The plot with fold changes and 95% confidence intervals shows consistent up-regulation of *CAMK2B* in the PFC of suicide victims as compared to the non-suicide controls across nine microarray studies. A combined analysis shown on the bottom represents the weighted fold change and 95% confidence intervals. Individual microarray probes for *CAMK2B* across multiple studies are shown on the left (Study ID and Affymetrix probe ID). Red circle: adjusted *p* \< 0.05, Cyan circle: adjusted *p* \> 0.05.](fnbeh-05-00046-g001){#F1}

The expression levels of *CDK5* in the PFC during postnatal development show inverted U-shape (Figure [2](#F2){ref-type="fig"}A). Specifically, the expression levels of *CDK5* in the PFC were increased until 10 years of age (*r*^2^ = 0.18, *q*v = 0.035) and then gradually decreased until 49 years (*r*^2^ = 0.23, *q*v = 0.029). A combined analysis of the microarray studies shows that *CDK5* expression levels are increased in the PFC of suicide victims as compared to the non-suicide subjects (FC: 1.19, *q*v = 0.04) as shown in Figure [2](#F2){ref-type="fig"}B. Individual studies did not show significant changes but a combined analysis (shown on the bottom) showed a significant up-regulation of *CDK5* in the PFC of suicide victims.

![**The expression profiles of ***CDK5*** in the PFC of normal developing individuals and suicide victims**. **(A)** The scatter plot with a locally weighted scatter plot smoothing (LOWESS) line demonstrates inverted U-shape expression pattern of *CDK5* in the PFC of normal humans ranging in age from birth to 49 years. Points are colored by the predefined age groups: red = neonate, green = infant, blue = toddler, light blue = school age, pink = teenage, yellow = young adult, gray: adult. **(B)** The plot with fold changes and 95% confidence intervals shows consistent up-regulation of *CDK5* in the PFC of suicide victims as compared to the non-suicide controls across nine microarray studies. A combined analysis shown on the bottom represents the weighted fold change and 95% confidence intervals. Individual microarray probes for *CDK5* across multiple studies are shown on the left (Study ID and Affymetrix probe ID). Red point: adjusted *p* \< 0.05, Cyan point: adjusted *p* \> 0.05.](fnbeh-05-00046-g002){#F2}

Figure [3](#F3){ref-type="fig"}A shows that the expression levels of mitogen-activated protein kinase 9 (*MAPK9*) in the PFC are gradually increased in the PFC of normal individuals ranging in age from birth to 49 years (*r*^2^ = 0.64, *q*v = 1.2E-05). The expression levels consistently increased until 20 years of age then stabilized until 49 years. In the PFC of suicide victims, *MAPK9* expression levels were increased as compared to the non-suicide subjects (FC: 1.21, *q*v = 0.002) as shown in Figure [3](#F3){ref-type="fig"}B. Each study has two microarray probes for *MAPK9* and most of the probes showed a tendency toward increase in expression. A combined analysis of microarrays revealed increased expression levels of *MAPK9* in the suicide victims as compared to the non-suicide controls.

![**The expression profiles of ***MAPK9*** in the PFC of normal individuals and of suicide victims**. **(A)** The scatter plot with a locally weighted scatter plot smoothing (LOWESS) line demonstrates gradual increases in expression of *MAPK9* in the PFC of normal humans ranging in age from birth to 49 years. Points are colored by the predefined age groups: red = neonate, green = infant, blue = toddler, light blue = school age, pink = teenage, yellow = young adult, gray: adult. **(B)** The plot with fold changes and 95% confidence intervals shows consistent up-regulation of *MAPK9* in the PFC of suicide victims as compared to the non-suicide controls across nine microarray studies. A combined analysis shown on the bottom represents the weighted fold change and 95% confidence intervals. Individual microarray probes for *MAPK9* across multiple studies are shown on the left (Study ID and Affymetrix probe ID). Red point: adjusted *p* \< 0.05, Cyan point: adjusted *p* \> 0.05.](fnbeh-05-00046-g003){#F3}

A developmental expression pattern of the protein kinase C iota (*PRKCI*) gene showed a gradual decrease in the PFC of normal individuals ranging in age from birth to 49 years (*r*^2^ = 0.66, *q*v = 4.2E-06) as shown in Figure [4](#F4){ref-type="fig"}A. A combined analysis of the microarrays showed that *PRKCI* expression levels were increased in the PFC of suicide victims as compared to the non-suicide subjects (FC: 1.14, *q*v = 0.015) shown in Figure [4](#F4){ref-type="fig"}B. Each microarray study has three probes for *PRKCI* and two studies (Study ID 2 and 3) did not show any changes in *PRKCI* expression while the rest of studies showed a tendency toward increase in expression. A combined analysis of microarrays demonstrated small but consensus changes in expression levels of *PRKCI* in the suicide group as compared to the non-suicide group.

![**The expression profiles ***PRKCI*** in the PFC of normal developing individuals and suicide victims**. **(A)** The scatter plot with a locally weighted scatter plot smoothing (LOWESS) line demonstrates gradual decreases in expression of *PRKCI* in the PFC of normal humans ranging in age from birth to 49 years. Points are colored by the predefined age groups: red = neonate, green = infant, blue = toddler, light blue = school age, pink = teenage, yellow = young adult, gray: adult. **(B)** The plot with fold changes and 95% confidence intervals shows consistent up-regulation of *PRKCI* in the PFC of suicide victims as compared to the non-suicide controls across nine microarray studies. A combined analysis shown on the bottom represents the weighted fold change and 95% confidence intervals. Individual microarray probes for *PRKCI* across multiple studies are shown on the left (Study ID and Affymetrix probe ID). Red point: adjusted *p* \< 0.05, Cyan point: adjusted *p* \> 0.05.](fnbeh-05-00046-g004){#F4}

Discussion
==========

The mechanisms of suicide are complex mediated by the interaction of multiple factors including genes and environment (Brezo et al., [@B2]; Fiori et al., [@B9]). However, the search for specific genetic factors that contribute to the pathophysiology of suicide has been challenging (Mann et al., [@B24]; Tsai et al., [@B41]). Previous studies with rodent models with fear and stress suggested that kinase genes in the brain may play a role in fear and stress-related behavior (Kouzu et al., [@B20]; Li et al., [@B23]; Revest et al., [@B32]; Sananbenesi et al., [@B34]; Hains et al., [@B14]). Although fear and stress may contribute to suicidal behavior in humans, expression profiles of those kinases genes in suicide brains have not been well-characterized. Thus, we investigated the expression profiles of the kinase genes using the microarray data from a well-characterized cohort of postmortem brains of mood disorder patients who died with suicide and without suicide. We found that four kinase genes including *CAMK2b, CDK5, MAPK9, and PRKCI* undergo age-dependent changes in expression in the PFC of normal individuals ranging in age from birth to 49 years. The expression levels of the same genes were increased in the PFC of suicide victims as compared to the non-suicide controls. It is important to note that these genes have been implicated in the mechanisms of fear and stress-related disorders. Thus, these genes may also contribute to the pathophysiology of suicide via interactions with the fear and stress circuitry in the brain.

Here, we demonstrated the advantages of combining multiple microarray datasets to detect small but consensus changes in gene expression in the PFC of suicide victims. We found robust changes in gene expression in the PFC of normal individuals ranging in age from birth to 49 years, suggesting that chronological age is one of major factors affecting brain gene expression during development. We attempted to identify the genes that are associated with both chronological age and suicide phenotype in individuals with mood disorder. A recent study showed the advantage of performing the genetic analysis using only mood disorder subjects with or without suicide attempts (Perlis et al., [@B30]). Thus, we have taken a similar approach of comparing suicide vs. non-suicide among the mood disorder subjects. Because we used only mood disorder samples, we were able to minimize the potential confounding effects of comorbid psychiatric disorders in our analysis.

Although many kinases are involved in a complex network of intracellular phosphorylation, previous studies suggested that multiple kinase genes such as *PKC, CAMK, MAPK*, and *CDK* play a significant role in regulating fear memories (Schafe et al., [@B35]; Li et al., [@B23]; Frankland et al., [@B11]; Lepicard et al., [@B22]; Sananbenesi et al., [@B34]; Bergstrom et al., [@B1]). *CAMK2* including two splice variants, *CaMK2A* and *CaMK2B*, control dendritic growth and maturation in neurons, as well as phosphorylation of numerous receptors including GABAA receptor (Churn and Delorenzo, [@B6]) and NMDA glutamate receptor subunits (Rakic et al., [@B31]). *CAMK2* modulates catecholamine metabolism via phosphorylation of tyrosine hydroxylase in dopamine neurons (Seeman et al., [@B36]). Previous studies investigated the role of *CAMK2A and CAMK2B* in the postmortem brains of individuals with mood disorder. For example, a gene expression microarray study showed that *CAMK2A* expression levels were increased in the PFC of individuals with major depression (Tochigi et al., [@B39]). Another study replicated an up-regulation of *CAMK2A* in the PFC of individuals with major depression but not bipolar disorder using a real-time quantitative PCR (Novak et al., [@B28]). The authors showed that the expression levels of *CaMK2A and CAMK2B* were elevated in the depression subjects by 29 and 36%, respectively. Moreover, the increased levels in depression subjects were not altered by a history of antidepressant medication in that study. Here, we classified the mood disorder subjects into either the suicide or the non-suicide group and we had a slightly higher number of depression cases in the suicide group. Although the increased levels of *CAMK2B* in the suicide group may have been influenced by higher number of depression samples in the suicide group, this is unlikely because we adjusted for the mood disorder effects in the multiple regression analysis of suicide. Given that *CAMK2B* could phosphorylate and influence the activity of many neurotransmitter receptors as well as neuronal growth and pruning, its altered expression in both developing and suicide brains suggests an important role in fear and stress.

*CDK5* has been implicated in anxiety and stress-related disorders that may require the promotion of the fear extinction process, which is defined as the learned reduction of fear. Some of the roles of *CDK5* during neurodevelopmental processes, such as interactions with distinct cytoplasmic and synaptic target molecules, may be related to the synaptic plasticity underlying memory consolidation (Fischer et al., [@B10]). A study using genetic and pharmacological approaches showed that extinction of fear memory requires the down-regulation of *CDK5* in mice (Sananbenesi et al., [@B34]). The authors demonstrated that several key proteins associated with the *CDK5* pathway play a critical role in extinction of fear memory. Here, we found age-dependent changes in *CDK5* expression: up-regulation until 10 years of age and then gradual down-regulation until 49 years of age. This suggests that there is a sensitive period of *CDK5* expression in the PFC during postnatal development. Thus, any disruptions in normal gene expression changes during development may result in dysfunction of stress and fear mechanisms. Increases in *CDK5* levels in the PFC of suicide victims further suggest that fear learning and extinction mechanisms may be disrupted in the individuals with suicide.

*MAPK* signaling pathway is critical for cell division and differentiation in the hippocampus as well as subsequent synaptic plasticity and memory formation (Sweatt, [@B37]). Importantly, *MAPK* has been shown to be critical for the formation of new fear memories, as well as for extinction and reconsolidation of fear memories (Schafe et al., [@B35]; Herry et al., [@B16]; Bergstrom et al., [@B1]). These studies also support the role of neuronal plasticity in the PFC for fear extinction (Herry et al., [@B16]). Stress, acting via glucocorticoids, may directly interact with *MAPK* mediated neuronal plasticity. A study showed that activation of glucocorticoid receptors increased the expression and enzymatic activity of proteins associated with the *MAPK* signaling pathway in mouse hippocampus (Revest et al., [@B32]). Inhibition of the *MAPK* pathway in the hippocampus abolished the increases in contextual fear conditioning induced by glucocorticoids. These results suggest a functional interaction between glucocorticoids receptors and the *MAPK* system in fear learning and memory. An epigenetic study showed that *MAPK1* regulates hippocampal chromatin remodeling in memory formation (Chwang et al., [@B7]). The authors identified the mitogen- and stress-activated protein kinase 1 (MSK1), a nuclear kinase downstream of ERK, as an important regulator of chromatin remodeling in long-term memory formation. Here, we found that the expression levels of *MAPK9* in the PFC of normal individuals gradually increased until 20 years of age then stabilized during postnatal development. This suggests that there is an increased demand on *MAPK9* function in the PFC during the sensitive period of brain development. Moreover, abnormal increases in *MAPK9* levels in the PFC of suicide victims indicate a critical role of this gene in the pathophysiology of suicide.

Previous studies suggested that the protein kinase C (*PRKC*) gene is involved in fear memory and suicide. For example, a chronic administration of *PRKC* inhibitor staurosporine (0.1 mg/kg, for 14 days) significantly reduced the acquisition of conditioned fear in rats (Li et al., [@B23]). This supports the notion that *PRKC* plays a key role in synaptic plasticity underlying emotional learning and memory. However, it is important to note that the staurosporine is not a selective inhibitor of *PRKC* and therefore other kinases are also inhibited by this compound. A postmortem brain study examined potential association between the pathogenesis of teenage suicide and *PRKC* using 17 teenage suicide victims and 17 non-psychiatric control subjects (Pandey et al., [@B29]). Enzymatic activity, protein and mRNA levels of various *PRKC* isozymes (including *PRKC* alpha, beta, and gamma) were measured in the PFC and hippocampus of suicide and non-suicide groups. There were significant decreases in protein and mRNA levels of *PRKC* alpha, beta, and gamma isozymes in the PFC and hippocampus of suicide victims as compared to the non-psychiatric controls. However, potential confounding effects of comorbid psychiatric disorders in the suicide victims have not been controlled in that study. Moreover, another *PRKC* isozyme, *PRKC* iota (*PRKCI*), was not measured. Here, we showed that the expression levels of *PRKCI* in the PFC were gradually decreased across age from birth to 49 years of age and increased in the PFC of mood disorder patients with suicide as compared to the non-suicide mood disorder subjects. Consistent with our findings, a study demonstrated that inhibition of *PRKC* signaling protected dendritic spines in the PFC and restored working memory impairment caused by chronic stress (Hains et al., [@B14]). This suggests that stress and anxiety may disrupt *PRKC* signaling in the PFC and inhibition of *PRKC* function may be neuroprotective and beneficial for the treatment of anxiety disorders. Many biological functions are mediated through phosphorylation by *PRKC* in the brain and therefore, *PRKC* may be a potential target for therapeutic intervention in individuals with anxiety disorders and suicidal ideation.

Postmortem brain studies of psychiatric patients are often challenging because many known and unknown factors can affect gene expression profiles in the brain tissue. Biological effects are often hindered by relatively small sample sizes, small effect sizes and comorbid psychiatric disorders. Available clinical information from each patient is typically sparse so that unknown covariates may either confound or confuse gene expression findings in postmortem brains. Thus, appropriate statistical adjustment is critical to improve inferences in determining gene expression changes in the brain of suicide victims. Although gene expression studies using postmortem brain tissue may reveal valuable information related to suicide, this approach alone is limited in terms of being able to distinguish between changes reflecting the primary disease etiology from those reflecting compensatory mechanisms and many potential confounding influences such as medication and substance use. Thus, it is important to study the functional role of these kinase genes that are being differentially expressed in the PFC of suicide victims as compared to the non-suicide subjects. In order to allow for a conclusive evaluation of the current findings, replication studies using independent samples as well as functional *in vitro* assays and pharmacological studies in animals are warranted. More research is needed to better understand the significance of the kinase genes that may be involved in the pathophysiology of suicide.

Conclusion
==========

We identified four kinase genes including *CAMK2B, CDK5, MAPK9, and PKCI* that show both age-dependent changes in normal individuals as well as pathological changes in suicide victims. Importantly, these kinases are critical for fear and stress associated neuronal plasticity. Given that these genes play a critical role in the mechanisms of fear and stress, abnormal changes in expression in the PFC of suicide victims further suggest overlapping biological pathways between fear, stress, and suicide. Thus, any disruptions in normal expression changes during the sensitive period of postnatal development may result in dysfunction of those genes that contribute to the pathophysiology of suicide in adulthood. A better understanding of the kinase genes and their interaction with environmental factors may help to develop novel strategies for suicide prevention.
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